ASX - By Stock
|
IXC |
Re:
Ann: First Patient Randomised in IIH EVOLVE Phase III Trial
|
|
SSilverstein
|
55 |
10K |
0 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
55
|
10K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
0 |
18/11/22 |
18/11/22 |
ASX - By Stock
|
30
|
5.5K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
2 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
30
|
5.5K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
2 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
30
|
5.5K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
1 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
30
|
5.5K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
0 |
02/11/22 |
02/11/22 |
ASX - By Stock
|
26
|
3.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
1 |
02/11/22 |
02/11/22 |
ASX - By Stock
|
26
|
3.9K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
3 |
28/10/22 |
28/10/22 |
ASX - By Stock
|
26
|
3.9K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
0 |
28/10/22 |
28/10/22 |
ASX - By Stock
|
26
|
3.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
1 |
28/10/22 |
28/10/22 |
ASX - By Stock
|
26
|
3.9K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
2 |
27/10/22 |
27/10/22 |
ASX - By Stock
|
26
|
3.9K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
26 |
3.9K |
0 |
27/10/22 |
27/10/22 |
ASX - By Stock
|
26
|
3.9K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Upcoming Presentation at Argonaut Biotech Briefing
|
|
SSilverstein
|
10 |
1.8K |
1 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
10
|
1.8K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Upcoming Presentation at Argonaut Biotech Briefing
|
|
SSilverstein
|
10 |
1.8K |
0 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
10
|
1.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Upcoming Presentation at Argonaut Biotech Briefing
|
|
SSilverstein
|
10 |
1.8K |
0 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
10
|
1.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Upcoming Presentation at Argonaut Biotech Briefing
|
|
SSilverstein
|
10 |
1.8K |
0 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
10
|
1.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Upcoming Presentation at Argonaut Biotech Briefing
|
|
SSilverstein
|
10 |
1.8K |
0 |
26/10/22 |
26/10/22 |
ASX - By Stock
|
10
|
1.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
1 |
25/10/22 |
25/10/22 |
ASX - By Stock
|
30
|
5.5K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
|
|
SSilverstein
|
8 |
1.5K |
0 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
8
|
1.5K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: First Australian Site Activated in IIH EVOLVE Phase 3
|
|
SSilverstein
|
3 |
905 |
2 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
3
|
905
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
|
|
SSilverstein
|
8 |
1.5K |
0 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
8
|
1.5K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
1 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
0 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
2 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
0 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
5 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
SSilverstein
|
30 |
5.5K |
2 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
30
|
5.5K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
1 |
21/10/22 |
21/10/22 |
ASX - By Stock
|
142
|
38K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
0 |
18/10/22 |
18/10/22 |
ASX - By Stock
|
142
|
38K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
0 |
14/10/22 |
14/10/22 |
ASX - By Stock
|
142
|
38K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
5 |
07/10/22 |
07/10/22 |
ASX - By Stock
|
142
|
38K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
5 |
07/10/22 |
07/10/22 |
ASX - By Stock
|
142
|
38K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
$3.38 Valuation | $0.60c Current SP | Fully Funded Phase 3 with First Patient in Coming Months
|
|
SSilverstein
|
142 |
38K |
2 |
06/10/22 |
06/10/22 |
ASX - By Stock
|
142
|
38K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
0 |
06/10/22 |
06/10/22 |
ASX - By Stock
|
15
|
4.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
3 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
15
|
4.8K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
2 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
15
|
4.8K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
3 |
05/10/22 |
05/10/22 |
ASX - By Stock
|
15
|
4.8K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
5 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
15
|
4.8K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
|
SSilverstein
|
15 |
4.8K |
1 |
30/09/22 |
30/09/22 |
ASX - By Stock
|
15
|
4.8K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
13 |
01/09/22 |
01/09/22 |
ASX - By Stock
|
47
|
13K
|
13
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
1 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
9 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
47
|
13K
|
9
|
|
ASX - By Stock
|
IXC |
Re:
ClinicalTrials.gov - IHH EVOLVE - We are in the system !
|
|
SSilverstein
|
28 |
6.8K |
0 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
28
|
6.8K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
3 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
47
|
13K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
4 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
47
|
13K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: 4E and Annual Report to shareholders
|
|
SSilverstein
|
2 |
1.3K |
4 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
2
|
1.3K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
1 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
0 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
47
|
13K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
SSilverstein
|
47 |
13K |
3 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
47
|
13K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
SSilverstein
|
39 |
7.5K |
0 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
39
|
7.5K
|
0
|
|